Trial Profile
A Twelve-Month Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Chinese Postmenopausal Women With Osteoporosis at Increased Risk of Fracture
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 28 Sep 2014 Planned primary completion date changed to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 28 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.